NDAINHALATIONSOLUTION
Approved
Oct 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
10
Mechanism of Action
[see Clinical Pharmacology ( )] .
Pharmacologic Class:
Aminoglycoside Antibacterial
Indications (1)
Clinical Trials (5)
Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
Started Feb 2017
107 enrolled
Non-cystic Fibrosis Bronchiectasis
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
Started Jan 2014
32 enrolled
Cystic Fibrosis
Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)
Started Aug 2013
60 enrolled
Cystic Fibrosis
Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Started Jan 2012
157 enrolled
Pulmonary InfectionsPseudomonas Aeruginosa in Cystic Fibrosis
Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
Started Jan 2011
282 enrolled
Cystic Fibrosis